Vinci Capital

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

OMNISENS was created in 1999 as a spin-off company of the Swiss Federal Institute of Technology (EPFL ). Omnisens produces instrumentation and systems based on optical metrology and photonics. Using fiber optic-based sensing Omnisens offers continuous, reliable monitoring for energy industry assets. A range of solutions is available for early detection and location of events which may threaten the integrity of the asset. These techniques provide condition monitoring, asset optimization and intrusion detection, based on small changes in temperature, strain and vibration. Monitoring techniques include Brillouin-based Distributed Temperature and Strain Sensing (DTSS), which Omnisens pioneered, Raman Distributed Temperature Sensing(DTS), Distributed Acoustic/Vibration Sensing (DAS/DVS) and Fiber Bragg Gratings (FBG). Based in Switzerland Omnisens operates throughout the world, either directly or through specialized solution providers, via dedicated application, commissioning and customer service teams. A leader in long-distance fiber optic sensing, Omnisens has pioneered effective real-time asset integrity monitoring solutions for critical oil and gas, power and civil engineering infrastructures.

Immatics US Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient, where they recognize and kill tumor cells. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company has a strategic cancer immunotherapy collaboration with Roche to research, develop, and commercialize various new cancer peptide antigen-based immunotherapies for targeting primarily gastric, prostate, and non-small cell lung cancer. Immatics US Inc. was founded in 2015 and is headquartered in Houston, Texas. Immatics US Inc. operates as a subsidiary of immatics biotechnologies GmbH.

SolvAxis is a leader in the design of ERP systems for SMEs . Since 1987, they offer enterprise software and related services. Their innovative and reliable ProConcept ERP solution lets you create and manage your business processes efficiently. 15'000 users on more than 1000 sites are already working with this standard solution. They are more and more numerous every day. Relationships with their customers, prospects and partners are based on mutual trust. Thus, their employees give your project a great importance. They collaborate with you in a close and constructive way.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment. Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Datamars was founded in 1988 as a joint venture between the technology companies Datalogic and Audemars to develop, design and manufacture state-of-the-art RFID solutions. The company quickly established itself as a world leader in RFID solutions for the animal and textile identification markets.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

Happiness is the best driver for success. Their mission is to make the workforce of their customers happy. beqom drives happiness by allowing business managers to lead, align and motivate employees and partners. The beqom Total Compensation platform is used globally across all industry sectors by over 100 large companies such as Microsoft and Vodafone. It addresses all Performance and Compensation aspects such as Salary Review, Bonus, Long-Term Incentives, Commissions, Benefits, Non-cash rewards and all key drivers towards Employee Performance and Sales Performance. HR, Sales and Finance organizations leverage their platform to drive performance, retention, cost optimization and... happiness among their people. beqom – to make your people happy.

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment. Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.